Having a Baby at 40 Is a Loan Now

Births to women over 40 are climbing fast, and it's the least-insured, most expensive corner of fertility. Private credit is filling the gap.

For the first time in the history of US vital statistics, women in their early 40s are having babies at a higher rate than teenagers.

Federal birth data show the rate for women 40 to 44 has edged past the rate for girls 15 to 19, a gap that ran the other way for the entire span of modern record-keeping, back to 1933.

The birth rate for women 40 to 44 rose 127% between 1990 and 2023. The teen birth rate fell roughly 73% over the same window. One cohort was climbing while the other collapsed, and in the last two years they met.

This got covered everywhere as a lifestyle shift. It's a financing shift, and the money is already moving.

Having a baby later usually means having it with help.

Fertility drops sharply after 40, so most late motherhood runs on IVF, egg-freezing, and donor eggs. Assisted-reproduction births more than doubled in under twenty years, from fewer than 45,000 in 2003 to over 97,000 by 2021, per the CDC. The fastest-growing group of new mothers is the most treatment-dependent one.

Treatment is expensive.

IVF runs $15,000 to $30,000 a cycle, and most patients need more than one. Almost no one covers it. A 2026 survey of employers of all sizes found just 30% pay for IVF. State mandates miss most people, because self-funded company plans, about two-thirds of insured workers per KFF, sit outside them. The cohort growing fastest is the one insurance reaches least.

When benefits don't pay, someone lends. A whole tier of companies now finances fertility: Future Family and CapexMD write loans, ARC and BUNDL package cycles with refund guarantees. Most of it is lending in the old sense. The company advances the money, and the patient still carries the risk of a cycle that doesn't work.

That layer is filling up fast, and it competes on rates and terms, the way lenders always do. The more interesting ground is the other side of the risk.

A newer model moves the risk off the patient and onto the financier. Gaia, which secured a $100 million credit facility from Viola Credit in May 2026, prices the odds of a live birth rather than the number of procedures.

Sunfish has built AI-driven forecasting to price cost and success before treatment starts. Here the company wins or loses on whether it can predict an outcome, not on whether it can collect a payment.

That is the harder business, and the more defensible one.

Pricing a live birth means pricing this exact cohort, where the odds are steepest. Cumulative live birth rates using a woman's own eggs fall to about 10% at 43 and keep dropping each year after, against roughly 40% under 35, per SART.

The demand is concentrated where the math is hardest, which is precisely why accurate prediction is worth so much. A model that knows who will actually have a baby is the asset.

The birth-rate crossover isn't a demographic milestone. It's demand, arriving in the least-insured corner of women's health, and the companies that can price it are about to matter more than the ones that can only lend into it.